Helicase-primase inhibitor pritelivir for HSV-2 infection

New England Journal of Medicine

Volumn 370, Issue 3, 2014, Pages 201-210

  Wald, Anna ^a   Corey, Lawrence ^a   Timmler, Burkhard ^b   Magaret, Amalia ^a   Warren, Terri ^c   Tyring, Stephen ^d   Johnston, Christine ^a   Kriesel, John ^e   Fife, Kenneth ^f   Galitz, Lawrence ^g   Stoelben, Susanne ^b   Huang, Meei Li ^a   Selke, Stacy ^a   Stobernack, Hans Peter ^b   Ruebsamen Schaeff, Helga ^b   Birkmann, Alexander ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AiCuris GmbH   (Germany)

^c Westover Heights Clinic   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Cetero Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIC 316; ANTIVIRUS AGENT; BAY 57 1293; DNA PRIMASE; HELICASE; PLACEBO; PRITELIVIR; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENITAL HERPES; HEADACHE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARALLEL DESIGN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RISK FACTOR; UPPER ABDOMINAL PAIN; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 84892608050     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1301150     Document Type: Article

References (21)

1. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A 1977;74:5716-20.
2. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984;310:1551-6.
3. Johnston C, Saracino M, Kuntz S, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 2012; 379:641-7. [Erratum, Lancet 2012;379:616.]
4. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20.
5. Crumpacker CS, Schnipper LE, Marlowe SI, Kowalsky PN, Hershey BJ, Levin MJ. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 1982;306:343-6.
6. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163: 76-80.
7. Kleymann G, Fischer R, Betz UA, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002;8:392-8.
8. Betz UA, Fischer R, Kleymann G, Hendrix M, Rübsamen-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob Agents Chemother 2002;46:1766-72.
9. Biswas S, Jennens L, Field HJ. The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res 2007;75:30-5.
10. Baumeister J, Fischer R, Eckenberg P, Henninger K, Ruebsamen-Waigmann H, Kleymann G. Superior efficacy of heli-case-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir Chem Chemother 2007;18: 35-48.
11. Birkmann A, Kropeit D, McCormick D, Zimmerman H, Ruebsamen-Schaeff H. Safety and human pharmacokinetics of AIC316, a potent helicase-primase inhibitor of herpes simplex virus. Presented at the 24th International Conference on Antiviral Research Sofia, Bulgaria, May 8-11, 2011. abstract.
12. Wald A, Zeh JE, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
13. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988;26:662-7.
14. Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003;188:1345-51.
15. Magaret AS, Wald A, Huang ML, Selke S, Corey L. Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol 2007;45:1618-20.
16. Field HJ, Biswas S. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus. Drug Resist Update 2011;14:45-51.
17. Rosenblum BB, Lee LG, Spurgeon SL, et al. New dye-labeled terminators for improved DNA sequencing patterns. Nucleic Acids Res 1997;25:4500-4.
18. Heiner CR, Hunkapiller KL, Chen SM, Glass JI, Chen EY. Sequencing multi-megabase-template DNA with BigDye terminator chemistry. Genome Res 1998;8: 557-61.
19. Dolan A, Jamieson FE, Cunningham C, Barnett BC, McGeoch DJ. The genome sequence of herpes simplex virus type 2. J Virol 1998;72:2010-21.
20. Schiffer JT, Wald A, Selke S, Corey L, Magaret A. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J Infect Dis 2011;204:554-61.
21. Magaret AS, Johnston C, Wald A. Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex Transm Infect 2009;85:270-5.